MicroRNA expression in acute myeloid leukemia

Current Hematologic Malignancy Reports

Volumn 4, Issue 2, 2009, Pages 83-88

  Marcucci, Guido ^a   Radmacher, Michael D ^a   Mrózek, Krzysztof ^a   Bloomfield, Clara D ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; HOMEODOMAIN PROTEIN; MICRORNA; NUCLEOPHOSMIN; STEM CELL FACTOR; TRANSCRIPTION FACTOR ERG;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME 13P; CHROMOSOME 21Q; CHROMOSOME 22Q; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME INVERSION 16; CHROMOSOME INVERSION 3; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 3; CHROMOSOME TRANSLOCATION 8; CHROMOSOME TRANSLOCATION 9; CYTOGENETICS; DOWN REGULATION; GENE CLUSTER; GENE DUPLICATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY; HUMAN; LEUKEMOGENESIS; PHENOTYPE; PROGNOSIS; REVIEW; UPREGULATION;

EID: 63549137947     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-009-0012-7     Document Type: Review

References (51)

1. Estey EH, Döhner H: Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
2. Ries LAG, Melbert D, Krapcho M, et al. (eds): SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2005/.
3. Estey EH: Treatment of acute myeloid leukemia. Haematologica 2009, 94:10-16.
4. Mrózek K, Marcucci G, Paschka P, et al.: Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood 2007, 109:431-448.
5. Döner K, Döner H: Molecular characterization of acute myeloid leukemia. Haematologica 2008, 93:976-982.
6. Schlenk RF, Döner K, Krauter J, et al.: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
7. Arber DA, Vardiman JW, Brunning RD, et al.: Acute myeloid leukaemia with recurrent genetic abnormalities. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Edited by Swerdlow SH, Campo E, Harris NL, et al. Lyon: IARC Press; 2008:110-123.
8. Fröhling S, Döhner H: Chromosomal abnormalities in cancer. N Engl J Med 2008, 359:722-734.
9. Mrózek K, Bloomfield CD: Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2006, 169-177.
10. Grimwade D, Walker H, Harrison G, et al.: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
11. Byrd JC, Mrózek K, Dodge RK, et al.: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
12. Slovak ML, Kopecky KJ, Cassileth PA, et al.: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000, 96:4075-4083.
13. Paschka P, Marcucci G, Ruppert AS, et al.: Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2008, 26:4595-4602.
14. Virappane P, Gale R, Hills R, et al.: Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008, 26:5429-5435.
15. Marcucci G, Maharry K, Whitman SP, et al.: High expression levels of the ETS - related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2007, 25:3337-3343.
16. Langer C, Radmacher MD, Ruppert AS, et al.: High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study. Blood 2008, 111:5371-5379.
17. Heuser M, Beutel G, Krauter J, et al.: High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006, 108:3898-3905.
18. Döhner K, Schlenk RF, Habdank M, et al.: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 2005, 106:3740-3746.
19. Paschka P, Marcucci G, Ruppert AS, et al.: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin Oncol 2006, 24:3904-3911.
20. Mrózek K, Marcucci G, Paschka P, Bloomfield CD: Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol 2008, 20:711-718.
21. Wouters BJ, Löwenberg B, Delwel R: A decade of genome-wide gene expression profiling in acute myeloid leukemia: Flashback and prospects. Blood 2009, 113:291-298.
22. Golub TR, Slonim DK, Tamayo P, et al.: Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
23. Verhaak RG, Wouters BJ, Erpelinck CAJ, et al.: Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 2009, 94:131-134.
24. Valk PJM, Verhaak RGW, Beijen MA, et al.: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617-1628.
25. Bullinger L, Döhner K, Bair E, et al.: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004, 350:1605-1616.
26. Radmacher MD, Marcucci G, Ruppert AS, et al.: Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: A Cancer and Leukemia Group B study. Blood 2006, 108:1677-1683.
27. Metzeler KH, Hummel M, Bloomfield CD, et al.: An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008, 112:4193-4201.
28. BarteG DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
29. Ambros V: The functions of animal microRNAs. Nature 2004, 431:350-355.
30. Gregory RI, Shiekhattar R: MicroRNA biogenesis and cancer. Cancer Res 2005, 65:3509-3512.
31. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
32. Calin GA, Sevignani C, Dumitru CD, et al.: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101:2999-3004.
33. Garzon R, Croce CM: MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 2008, 15:352-358.
34. Chang TC, Yu D, Lee YS, et al.: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008, 40:43-50.
35. Mi S, Lu J, Sun M, et al.: MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A 2007, 104:19971-19976.
36. Li Z, Lu J, Sun M, et al.: Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 2008, 105:15535-15540.
37. Dixon-McIver A, East P, Mein CA, et al.: Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS ONE 2008, 3:e2141.
38. Jongen-Lavrencic M, Sun SM, Dijkstra MK, et al.: MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008, 111:5078-5085.
39. Garzon R, Volinia S, Liu CG, et al.: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111:3183-3189.
40. Garzon R, Garofalo M, Martelli MP, et al.: Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008, 105:3945-3950.
41. O'Connell RM, Rao DS, Chaudhuri AA, et al.: Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008, 205:585-594.
42. Marcucci G, Maharry K, Radmacher MD, et al.: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B study. J Clin Oncol 2008, 26:5078-5087.
43. Hackanson B, Bennett KL, Brena RM, et al.: Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res 2008, 68:3142-3151.
44. Debernardi S, Skoulakis S, Molloy G, et al.: MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia 2007, 21:912-916.
45. Isken F, Steffen B, Merk S, et al.: Identification of acute myeloid leukaemia associated microRNA expression patterns. Br J Haematol 2008, 140:153-161.
46. Marcucci G, Radmacher MD, Maharry K, et al.: MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1919-1928.
47. Mariathasan S, Monack DM: Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 2007, 7:31-40.
48. Choong ML, Yang HH, McNiece I: MicroRNA expression profiling during human cord blood-derived CD34 cell erythropoiesis. Exp Hematol 2007, 35:551-564.
49. BaltimNre D, Boldin MP, O'Connell RM, et al.: Micro-RNAs: new regulators of immune cell development and function. Nat Immunol 2008, 9:839-845.
50. Taganov KD, Boldin MP, Chang K-J, Baltimore D: NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006, 103:12481-12486.
51. Yang M, Mattes J: Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. Pharmacol Ther 2008, 117:94-104.